Disappointingly, the findings of the long-running GEFPCAPI trial led by Dr Fizazi of the Institut Gustave Roussy have proved negative. The trial has concluded that: “In GEFCAPI 04, using a molecular test followed by tailored systemic treatment did not improve outcomes of patients with carcinomas of the unknown primary site.” The trial ran from March 2012 to February 2018 inRead more